Reneuron Group (RENE)


Latest News

ReNeuron shareholders approval capital re-organisation

ReNeuron Group said shareholders had approved a re-organisation of its share capital at a general meeting. All shareholde...

Further re Share Capital Reorganisation

RNS Number: 5473B ReNeuron Group plc 11 January 2018 11 January 2018 AIM: RENE ReNeuron Group plc ("ReNeuron" or the "Company") Share Capital Reorganisation - Allotment of Ordinary Shares & Irrevocable Undertaking Capitalised terms not otherwise defined herein shall have the same meaning given to such terms in the circular issued by the Compan...

ReNeuron Group plans share reduction

ReNeuron Group has launched a capital reorganisation what will reduce the number of shares in the company by a facto...

Proposed Share Capital Reorganisation

RNS Number: 0371B ReNeuron Group plc 05 January 2018 5 January 2018 AIM: RENE ReNeuron Group plc ("ReNeuron" or the "Company") Proposed Share Capital Reorganisation and Notice of General Meeting Share consolidation to increase the price of each share to improve marketability, liquidity and trading activity ReNeuron Group plc (AIM: RENE), a UK...

All News

23-01-18ReNeuron shareholders approval capital re-organisationStockMarketWire
11-01-18Further re Share Capital ReorganisationRNS
05-01-18ReNeuron Group plans share reductionStockMarketWire
05-01-18Proposed Share Capital ReorganisationRNS
14-12-17ReNeuron losses widenStockMarketWire
14-12-17Interim resultsRNS
14-12-17Stroke clinical trial regulatory approval in USRNS
08-12-17ReNeuron Group opens Boston officeStockMarketWire
08-12-17ReNeuron opens US officeRNS
13-11-17Notification of Interim ResultsRNS
08-11-17ReNeuron clinical trial enters next phaseStockMarketWire
08-11-17Retinal disease clinical trial moves into Phase IIRNS
31-10-17ReNeuron reports positive trial dataStockMarketWire
31-10-17Positive stroke clinical data & regulatory updateRNS
27-10-17ReNeuron wins Welsh grantStockMarketWire
27-10-17Wins further UK grantRNS
11-10-17PDMR Interest in Shares and Share OptionsRNS
09-10-17Presentation of positive pre-clinical dataRNS
12-09-17Directors' Interest in Shares and Share OptionsRNS
06-09-17Result of AGMRNS
06-09-17AGM Trading UpdateRNS
01-09-17Non-executive Director AppointmentRNS
01-09-17Block Listing Review and TVRRNS
07-08-17Neil Woodford 'very confident' he can deliver 10%-plus yearly returnsMoney Observer
07-08-17Posting of Annual Report and Notice of AGMRNS
04-08-17Second Price Monitoring ExtnRNS
04-08-17Price Monitoring ExtensionRNS
25-07-17Appointment of joint brokerRNS
19-07-17Board changeRNS
29-06-17ReNeuron widens FY pretax lossStockMarketWire
29-06-17Preliminary ResultsRNS
19-06-17ReNeuron says FDA okays cryopreserved hRPC formulationStockMarketWire
19-06-17FDA approves cryopreserved hRPC formulationRNS
08-06-17Notification of Preliminary ResultsRNS
05-06-17ReNeuron gets favourable feedback from US FDAStockMarketWire
05-06-17Positive FDA feedback on proposed Phase III studyRNS
18-05-17ReNeuron presents positive exosome dataStockMarketWire
18-05-17Presents positive exosome data at major conferenceRNS
11-05-17ReNeuron awarded £1.8m grant from Innovate UKStockMarketWire
11-05-17Awarded major UK cell therapy manufacturing grantRNS

RSS feeds

  • Editorial news feed for LSE:RENE Editorial
  • Regulatory news feed for LSE:RENE Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account